Glenmark Life Sciences (GLS), recently got listed in the stock market and is trading at a 5 to 7% discount to its IPO price. The company has a solid business model, robust financials and good growth potential.
It has stringent focus on quality. It has received zero warning letters or import alerts from leading FDAs across the globe like USFDA, Health Canada, EU Regulator bodies since 2015 (Its facilities are inspected approximately 38 times in the last 5-6 years) and this is an envious record. Can GLS deliver multibagger returns in future? Watch out for this video to know about the company’s business, its products, Moat, Growth Levers, Key Concerns and financials so that you can take an informed decision on GLS stock investment.
#Multibagger, #GLS
Magic Box
0:00 Introduction
2:52 Agenda
3:40 About Company-Products & Services
10:38 Key Therapies
11:31 Company Moat
13:13 Future Growth Levers
15:35 Weakness / Concerns
Source of Information – DRHP document, Company Website, IPO research report from HDFC Securities, discussion on valuepickr.com.
The template for the beautiful presentation in the video is downloaded from ‘http://www.free-powerpoint-templates-design.com’.
Disclaimer - The companies covered in the stock analysis series are by no means a buy or sell recommendation. These videos are created purely for educational purposes. An investor is further expected to do his or her own research before making a buy or sell decision
0 Comments